Shelley Sassaman
Medical · Tamaqua, PANPI 1609875632
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $84,737 of the $90,487 with a category attached, or 93.6%. Medtronic accounts for 93.8% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2024 at $26,081 and has fallen 50.4% since, to $12,931 in 2025. Among medical clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 348 payments — averaging $260.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$85K
- Bayer$1K
- Novo Nordisk$816
- AstraZeneca$722
- Xeris Pharmaceuticals, Inc.$643
- Corcept Therapeutics$295
- plus $2K from 14 others
What the payments were for
- Consulting fees$6201%
- Speaking & faculty fees$84,73794%
- Food & beverage$4,9886%
- Education$830%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 70 | $84,840 |
| Bayer | 41 | $1,434 |
| Novo Nordisk | 46 | $816 |
| AstraZeneca | 35 | $722 |
| Xeris Pharmaceuticals, Inc. | 39 | $643 |
| Corcept Therapeutics | 19 | $295 |
| Lilly USA, LLC | 10 | $281 |
| Boehringer Ingelheim | 15 | $257 |
| Amgen | 18 | $240 |
| Mannkind Corporation | 11 | $198 |
| Sanofi-aventis U.S. LLC | 10 | $196 |
| Merck | 13 | $195 |
| Abbott | 6 | $103 |
| Insulet Corporation | 5 | $88 |
| Esperion Therapeutics, Inc. | 4 | $61 |
| Sequel Med Tech, LLC | 2 | $42 |
| IBSA Pharma Inc. | 1 | $23 |
| BETA Bionics, Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $18 |
| Radius Health, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$46,445
- MINIMED 770G$23,575
- Minimed 770G System$14,718
- Kerendia$858
- FARXIGA$125
- JARDIANCE$109
How this compares
$90,487 in reported general payments places this provider in the 95th percentile of 2,594 medical providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 110 | $144,032 |
| TrulicityDulaglutide | 48 | $63,975 |
| JardianceEmpagliflozin | 41 | $37,317 |
| KerendiaFinerenone | 42 | $33,851 |
| MounjaroTirzepatide | 27 | $33,035 |
| JanuviaSitagliptin Phosphate | 48 | $30,254 |
| FarxigaDapagliflozin Propanediol | 20 | $26,143 |
| Tresiba Flextouch U-100Insulin Degludec | 37 | $25,822 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 44 | $25,249 |
| EliquisApixaban | 21 | $21,833 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $19,509 |
| TradjentaLinagliptin | 33 | $17,065 |
| RybelsusSemaglutide | 11 | $13,633 |
| SynjardyEmpagliflozin/Metformin Hcl | 16 | $12,756 |
| NovologInsulin Aspart | 32 | $12,365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $816 | $170,029153 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $281 | $103,05595 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $257 | $67,13890 claims |
| MerckJanuvia, Janumet Xr, Janumet | $195 | $46,98273 claims |
| BayerKerendia | $1,434 | $33,85142 claims |
| AstraZenecaFarxiga | $722 | $26,14320 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $196 | $19,50913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,594 medical providers in Pennsylvania.
Other medical in Tamaqua
- Jacqueline KernaghanSpringfield$426K
- Drew SodaNew Hope$220K
- Angela KapalkoPhiladelphia$123K
- Linda PerryPhiladelphia$123K
- Cory DavidsonErie$119K
- Meghan HoffnerBethlehem$86K
- Thomas IacovoniDanville$72K
- Scott CoxWynnewood$66K
- Sarah SmithPhiladelphia$65K
- Patrick OffiPittsburgh$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.